Induction of osteogenic differentiation of MSCs by GSK3β knockdown through GSK3β siRNAs transfection.
Galitsyna EV., Buianova AA., Bukharova TB., Krivosheeva IA., Skoblov MY., Goldshtein DV.
Laboratory Study, published in PLoS One (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- PLoS One (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42566415
- DOI
- 10.1371/journal.pone.0355286
Abstract (original English)
The development of effective strategies for treating bone defects can be based on gene therapy methods aimed at regulating the differentiation of osteoprogenitor cells. One of the approaches is to use siRNA molecules in knockdown systems for genes inhibiting osteogenic cell differentiation. In this work, we aimed at developingapproaches to induce osteogenic differentiation of mesenchymal stem cells (MSCs) by siRNAs-mediated knockdown of GSK3β siRNAs in cultures of MSCs derived from human adipose tissue (AD-MSCs). For this purpose, we compared the transfection efficacy of lipoplexes and polyplexes formed with one of four siRNA molecules and five commercial transfection agents most commonly used in laboratory practice. The most effective transfection agent was found to be linear polyethylenimine (PEI) which demonstrated high cytocompatibility both in free form and in polyplexes (even when maximum concentrations were used). Using the polyplexes formed by the newly designed siRNA and PEI, we constructed a highly efficient GSK3β gene knockdown system, which showed effectiveness in AD-MSC cultures. As a result, we demonstrated the osteoinductive properties of GSK3β siRNA molecules in these cultures. These results provide a methodological basis for future siRNA-based strategies targeting GSK3β in osteogenic applications, with in vivo studies needed to establish its translational poten
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.